Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $166,564.81 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher John Kenney sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $166,564.81. Following the sale, the insider directly owned 4,729 shares in the company, valued at approximately $284,260.19. The trade was a 36.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christopher John Kenney also recently made the following trade(s):

• On Friday, March 13th, Christopher John Kenney sold 1,410 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $55.23, for a total transaction of $77,874.30.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $55.23 on Friday. The firm has a market cap of $4.59 billion, a price-to-earnings ratio of -12.67 and a beta of 0.91. The firm has a 50-day simple moving average of $43.71 and a two-hundred day simple moving average of $41.92. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter last year, the company posted ($0.84) EPS. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on XENE shares. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday. Robert W. Baird increased their price objective on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a report on Monday. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Guggenheim restated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday. Finally, HC Wainwright upped their target price on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $71.94.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of large investors have recently bought and sold shares of XENE. Elevation Point Wealth Partners LLC acquired a new position in Xenon Pharmaceuticals in the 2nd quarter worth approximately $32,000. Danske Bank A S acquired a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at approximately $32,000. Blue Trust Inc. boosted its holdings in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 717 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at $33,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the third quarter worth $39,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.